Cytokine accumulations in csf of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6

Neurology

Volumn 40, Issue 11, 1990, Pages 1735-1739

  Hauser, S L ^a   Doolittle, T H ^a   Lincoln, R ^a   Brown, R H ^a   Dinarello, C A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ARTICLE; CEREBROSPINAL FLUID; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

COMPARATIVE STUDY; HUMAN; INTERLEUKIN-1; INTERLEUKIN-6; LEUKOCYTE COUNT; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; RADIOIMMUNOASSAY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0025107677     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.40.11.1735     Document Type: Article

References (53)

1. Dinarello CA. Biology of interleukin-1. FASEB J 1988;2:108-115.
2. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211-1227.
3. Dinarello CA. Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). Year Immunol 1986;2:68-69.
4. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-1176.
5. Van Damme J, Billiau A. Identification of the human 26-kD protein, interferon beta-2, as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 1987;165:914-919.
6. Habicht GS, Beck G. IL-1 is an endogenous mediator of acute inflammation and of the local Schwartzman reaction. In: Kluger MJ, Oppenheim JJ, Powanda MD, eds. The physiologic, metabolic and immunobiologic actions of interleukin-1. NY: Alan R Liss, 1985:13-24.
7. Movat HZ, Cybulsky MI, Colditz IG, et al. Acute inflammation in gram negative infection: endotoxin, interleukin-1, tumor necrosis factor, and neurotrophil. Fed Proc 1987;46:97-104.
8. Fontana A, McAdam KPWJ, Kristensen F, et al. Biological and biochemical characterization of an interleukin-l-like factor from rat C6 glioma cells. Eur J Immunol 1983;13:685-689.
9. Giulian D, Baker TJ, Shih L-C N, Lachman LB. Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med 1986;164:594-604.
10. Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 1985;228:497-499.
11. Giulian D, Young DG, Woodward J, Brown DC, Lachman LB. Interleukin-1 is an astroglial growth factor in the developing brain. J Neurosci 1988;8:709-714.
12. Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreac- tive innervation of the human hypothalamus. Science 1988;240:321-324.
13. Krueger JM, Walter J, Dinarello CA, et al. Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 1984;246:R994-R999.
14. Coceani F, Lees J, Dinarello CA. Occurrence of interleukin-1 in cerebrospinal fluid of the conscious cat. Brain Res 1988;446:245-250.
15. Shoham S, Davenne D, Cady AB, Dinarello CA, Krueger JM. Recombinant tumor necrosis factor and interleukin-1 enhance slow-wave sleep. Am J Physiol 1987;253:R142-R149.
16. Moldolfsky H, Lue FA, Eisen J, Kewstone E, Gorczynski RM. The relationship of interleukin-1 and immune reactions to sleep in humans. Psychosom Med 1986;48:309-318.
17. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989;491:394-397.
18. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 1989;86:6348-6352.
19. Muraguchi A, Hirano T, Rang B, et al. The essential role of B cell stimulatory factor (FSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988;167:332-344.
20. Vink A., Coulie PG, Wauters P, Nordan RP, Van Snick J. B cell growth and differentiation activity of interleukin-HP 1 and related murine plasmocytoma growth factors. Synergy with interleukin-1. Eur J Immunol 1987;18:607-612.
21. Frei K, Malipiero U, Leist T, Zinkemagel R, Schwab M, Fontana A. On the cellular course and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J Immunol 1989;19:689-694.
22. Helle M, Brakenhoff JPJ, DeGroot ER, Aarden LA. Interleukin-6 is involved in interleukin-1 induced activities. Eur J Immunol 1988;18:957-959.
23. Leist TP, Frei K, Kam-Hansen S, Zinkemagel RM, Fontana A. Tumor necrosis factor A in cerebrospinal fluid during bacterial, but not viral, meningitis. J Exp Med 1988;167:1743-1748.
24. Waage A, Brandtzaeg P, Halstensen A, Kierule P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989;169:333-338.
25. Mustafa M, Mertsola J, Ramilo O, Saez-Llorens X, Risser R, McCracken G. Jr. Increased endotoxin and interleukin-1-p concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J Infect Dis 1989;160:891-895.
26. Hopkins SJ, Humphreys M, Jayson MIV. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988;72:422-427.
27. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:522-568.
28. Lisi PJ, Chu C-W, Koch GA, et al. Development and use of a radioimmunoassay for human interleukin-l-beta. Lymphokine Res 1987;6:229-244.
29. Van der Meer JWM, Endres S, Lonnemann G, et al. Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro. J Leukocyte Biol 1988;43:216-223.
30. Schindler R, Mancilla J, Endres S, et al. Correlations and interactions in the production of IL-6, IL-1 and TNF in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40-47.
31. Frei K, Leist TP, Meager A, et al. Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients. J Exp Med 1988;168:449-453.
32. Franciotta D, Grimaldi L, Martino G, et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989;26:787-789.
33. Blatteis CM. Neural mechanisms in the pyrogenic and acute- phase responses to interleukin-1. Int J Neurosci 1988;38:223-232.
34. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984;65:135-138.
35. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12:251-254.
36. Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. Arch Neurol 1988;45:435-437.
37. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14:273-278.
38. Hauser SL, Reinherz EL, Hoban CJ, et al. Immunoregulatory T- cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period. Ann Neurol 1983;13:418-425.
39. Martin-Mondiere C, Jacques C, Delassalle A, Cesaro P, Carydakis C, Degos JD. Cerebrospinal myelin basic protein in multiple sclerosis; identification of two groups of patients with acute exacerbation. Arch Neurol 1987;44:276-278.
40. Namerow NS. Circadian temperature rhythm and vision in multiple sclerosis. Neurology 1968;18:417-422.
41. Castaigne P, Escourolle R, Laplane D, Augustin P. Comas tran- sitoires avec hyperthermie au cours de la sclerose en plaques. Rev Neurol (Paris) 1966;114:147-150.
42. Nelson DA, McDowell F. The effects of induced hyperthermia on patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1959;22:113-116.
43. Malhotra AS, Goven H. The hot bath test in the diagnosis of multiple sclerosis. JAMA 1981;246:1113-1114.
44. Hofman FM, von Hanwehr RI, Dinarello CA, et al. Immu- noregulatory molecules and U-2 receptors identified in multiple sclerosis brain. J Immunol 1986;136:3239-3245.
45. Selmaj K, Nowak Z, Tchorzewski H. Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro. Clin Exp Immunol 1988;72:428-433.
46. Robbins D, Shirazi Y, Drysdale B, Lieberman A, Shin H, Shin M. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987;139:2593-2597.
47. Selmaj K, Raine C. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1989;23:339-346.
48. Lumsden CE. The neuropathology of multiple sclerosis. In: Handbook of clinical neurology, vol 9. Vinken PJ, Bruyn GW, eds. Multiple sclerosis and allied demyelinating diseases. Amsterdam: Elsevier Press, 1980:217-309.
49. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis—oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 1981;45:534-546.
50. Reier PJ, Houle JD. The glial scar: its bearing on axonal elongation and transplantation approaches to CNS repair. In: Waxman SG, ed. Functional recovery in neurological diseases. New York: Raven Press, 1988:87-138.
51. Endres S, Ghorbani BS, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;5:265-271.
52. Robertson B, Dostal K, Daynes RA. Neuropeptide regulation of inflammatory and immunologic responses: the capacity of alpha- melanocyte-stimulating hormone to inhibit tumor necrosis factor and IL-l-inducible biologic responses. J Immunol 1988;140:4300-4307.
53. Rosenstreich DL, Tu JH, Kinkade PR, et al. A human urine- derived interleukin 1 inhibitor. J Exp Med 1988;168:1767-1779.